Uniferon® approved in UK (replaces Leodex®)

May 18, 2006

Uniferon® has been approved by the Veterinary Medicines Directorate in the United Kingdom (UK) and replaces Leodex®. Uniferon® is Pharmacosmos' veterinary iron dextran compound for injection and the worldwide leading injectable iron dextran solution for prevention of iron deficiency anemia in piglets.

Leodex® in the UK

Since 1992, Pharmacosmos has supplied the active pharmaceutical ingredient (API) in Leodex® veterinary iron dextran solution for injection. Leodex® has been marketed by Leo Laboratories Ltd., a UK subsidiary of Danish-based pharmaceutical company Leo Pharma A/S. As a natural extension of Pharmacosmos' commitment the UK customers, Pharmacosmos is pleased to announce that the company agreed to acquire Leo Laboratories Ltd.'s marketing authorization of Leodex® earlier in 2006.

Uniferon® replaces Leodex®

As an important part of the procedure of acquiring the marketing authorization of Leodex®, Pharmacosmos has decided to let Uniferon® replace Leodex® as product name. This will allow UK customers to benefit from the strong awareness of the documented positive effects of Uniferon®. Today, Uniferon® has been approved by the UK Veterinary Medicines Directorate.

About Uniferon®

Injection of Uniferon® provides high 200 mg iron per ml for treatment and is an efficient method to prevent iron deficiency anemia. Ensuring healthy and vigorous growth in piglets, Uniferon® has been approved in all major countries including the United States (US).

Please read more information about Uniferon® or visit the Uniferon website.

About Pharmacosmos A/S

Pharmacosmos develops and markets medicines for the treatment of iron deficiency. A research-based company, its ongoing R&D programme focuses on improving the treatment options for healthcare professionals, patients suffering from iron deficiency and veterinary treatments. .

Pharmacosmos is a family-owned Danish company and operates in more than 50 countries across Europe, the Americas and Asia. Its facilities are approved by both the Danish Medicines Agency and the US Food & Drug Administration.